These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32715405)

  • 41. Screening and treatment for Alzheimer's disease: predicting population-level outcomes.
    Furiak NM; Kahle-Wrobleski K; Callahan C; Klein TM; Klein RW; Siemers ER
    Alzheimers Dement; 2012 Jan; 8(1):31-8. PubMed ID: 22265589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment.
    Frederiksen KS; Nielsen TR; Winblad B; Schmidt R; Kramberger MG; Jones RW; Hort J; Grimmer T; Georges J; Frölich L; Engelborghs S; Dubois B; Waldemar G
    Eur J Neurol; 2021 Jul; 28(7):2147-2155. PubMed ID: 33368924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years.
    Bradfield NI; Ellis KA; Savage G; Maruff P; Burnham S; Darby D; Lautenschlager NT; Martins RN; Masters CL; Rainey-Smith SR; Robertson J; Rowe C; Woodward M; Ames D
    Alzheimer Dis Assoc Disord; 2018; 32(3):190-196. PubMed ID: 29561277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conversion to dementia in mild cognitive impairment diagnosed with DSM-5 criteria and with Petersen's criteria.
    Marcos G; Santabárbara J; Lopez-Anton R; De-la-Cámara C; Gracia-García P; Lobo E; Pírez G; Menchón JM; Palomo T; Stephan BC; Brayne C; Lobo A;
    Acta Psychiatr Scand; 2016 May; 133(5):378-85. PubMed ID: 26685927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers.
    Vercruysse O; Paquet C; Gabelle A; Delbeuck X; Blanc F; Wallon D; Dumurgier J; Magnin E; Martinaud O; Jung B; Bousiges O; Lehmann S; Delaby C; Quillard-Murain M; Peoc H K; Laplanche JL; Bouaziz-Amar E; Hannequin D; Sablonniere B; Buee L; Hugon J; Schraen S; Pasquier F; Bombois S; For The E-Plm Group
    Curr Alzheimer Res; 2018; 15(7):691-700. PubMed ID: 29318973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic Behavior for Mild Cognitive Impairment in General and Neuropsychiatric Practices in Germany.
    Bohlken J; Kostev K
    J Alzheimers Dis; 2019; 68(3):925-930. PubMed ID: 30883363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease.
    Siafarikas N; Selbaek G; Fladby T; Šaltytė Benth J; Auning E; Aarsland D
    Int Psychogeriatr; 2018 Jan; 30(1):103-113. PubMed ID: 28927477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
    Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
    BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'?
    Davey DA
    Womens Health (Lond); 2013 May; 9(3):279-90. PubMed ID: 23638783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease.
    Forlenza OV; Diniz BS; Teixeira AL; Stella F; Gattaz W
    Braz J Psychiatry; 2013; 35(3):284-94. PubMed ID: 24142092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The process of disclosing a diagnosis of dementia and mild cognitive impairment: A national survey of specialist physicians in Denmark.
    Nielsen TR; Svensson BH; Rohr G; Gottrup H; Vestergaard K; Høgh P; Waldemar G
    Dementia (London); 2020 Apr; 19(3):547-559. PubMed ID: 29806491
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.
    Kida J; Nemoto K; Ikejima C; Bun S; Kakuma T; Mizukami K; Asada T
    J Alzheimers Dis; 2016; 51(2):405-15. PubMed ID: 26890740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Memory performance on the story recall test and prediction of cognitive dysfunction progression in mild cognitive impairment and Alzheimer's dementia.
    Park JH; Park H; Sohn SW; Kim S; Park KW
    Geriatr Gerontol Int; 2017 Oct; 17(10):1603-1609. PubMed ID: 27910252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation.
    Padovani A; Benussi A; Cantoni V; Dell'Era V; Cotelli MS; Caratozzolo S; Turrone R; Rozzini L; Alberici A; Altomare D; Depari A; Flammini A; Frisoni GB; Borroni B
    J Alzheimers Dis; 2018; 65(1):221-230. PubMed ID: 30010131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.